Literature DB >> 12920172

Substrate specificity and kinetic properties of seven heterologously expressed dog cytochromes p450.

Magang Shou1, Ryan Norcross, Grit Sandig, Ping Lu, Yinghe Li, Yuh Lin, Qin Mei, A David Rodrigues, Thomas H Rushmore.   

Abstract

Seven dog cytochromes p450 (p450s) were heterologously expressed in baculovirus-Sf21 insect cells. Of all enzymes examined, CYP1A1 exhibited high 7-ethoxyresorufin O-deethylase activity (low Km enzyme, 1 microM). CYP2B11 and CYP3A12 effectively catalyzed the N1-demethylation and C3-hydroxylation of diazepam (and its derivatives), whereas CYP3A12 and CYP2D15 catalyzed exclusively the N- and O-demethylation, respectively, of dextromethorphan. However, no saturation velocity curves for the N-demethylation of dextromethorphan (up to 500 microM) were achieved, suggesting a high Km for CYP3A12. In contrast to CYP3A12, the CYP2D15-dependent O-demethylation of dextromethorphan was a low Km process (Km = 0.7 microM), similar to that in dog liver microsomes (Km = 2.3 microM). CYP2D15 was also capable of metabolizing bufuralol (1'-hydroxylation), with a Km of 3.9 microM, consistent with that obtained with dog liver microsomes. CYP3A12 was shown to primarily oxidize testosterone at 16alpha-, 2alpha/2beta-, and 6beta-positions. Selectivity of CYP3A12 was observed toward testosterone 6beta-(Km = 83 microM) and 2alpha/2beta-hydroxylations (Km = 154 microM). However, the 16alpha-hydroxylation of testosterone was catalyzed by CYP2C21 also (Km = 6.4 microM for CYP2C21). Therefore, the 6beta- and 16alpha-hydroxylation of testosterone can potentially be employed as markers of CYP3A12 and CYP2C21 (at low concentration), respectively. CYP2C21 was also capable of catalyzing diclofenac 4'-hydroxylation, although some activity was detected with CYP2B11. Surprisingly, none of the p450s selectively metabolized (S)-mephenytoin 4'-hydroxylation. The results described herein are a first step toward the systematic evaluation of a panel of dog p450s and the development of dog p450 isoenzyme-selective marker substrates, as well as providing useful information on prediction and extrapolation of the results from in vitro to in vivo and from dog to human.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12920172     DOI: 10.1124/dmd.31.9.1161

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  11 in total

Review 1.  Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism.

Authors:  Thomas A Baillie; Allan E Rettie
Journal:  Drug Metab Pharmacokinet       Date:  2010-10-22       Impact factor: 3.614

2.  Absolute Quantitation of Drug-Metabolizing Cytochrome P450 Enzymes and Accessory Proteins in Dog Liver Microsomes Using Label-Free Standard-Free Analysis Reveals Interbreed Variability.

Authors:  Stephanie E Martinez; Jian Shi; Hao-Jie Zhu; Tania E Perez Jimenez; Zhaohui Zhu; Michael H Court
Journal:  Drug Metab Dispos       Date:  2019-08-19       Impact factor: 3.922

Review 3.  Use of in vivo animal models to assess pharmacokinetic drug-drug interactions.

Authors:  Cuyue Tang; Thomayant Prueksaritanont
Journal:  Pharm Res       Date:  2010-04-29       Impact factor: 4.200

4.  Mass spectrometry-based quantification of CYP enzymes to establish in vitro/in vivo scaling factors for intestinal and hepatic metabolism in beagle dog.

Authors:  Aki T Heikkinen; Arno Friedlein; Jens Lamerz; Peter Jakob; Paul Cutler; Stephen Fowler; Tara Williamson; Roberto Tolando; Thierry Lave; Neil Parrott
Journal:  Pharm Res       Date:  2012-02-22       Impact factor: 4.200

5.  Effect of cytochrome P450 inhibition on toxicity of diclofenac in chickens: Unravelling toxicity in Gyps vultures.

Authors:  Sara Locke; Vinny Naidoo; Ibrahim Hassan; Neil Duncan
Journal:  Onderstepoort J Vet Res       Date:  2022-06-14       Impact factor: 1.982

6.  Quantitative ADME proteomics - CYP and UGT enzymes in the Beagle dog liver and intestine.

Authors:  Aki T Heikkinen; Arno Friedlein; Mariette Matondo; Oliver J D Hatley; Aleksanteri Petsalo; Risto Juvonen; Aleksandra Galetin; Amin Rostami-Hodjegan; Ruedi Aebersold; Jens Lamerz; Tom Dunkley; Paul Cutler; Neil Parrott
Journal:  Pharm Res       Date:  2014-07-18       Impact factor: 4.200

7.  Canine cytochrome P-450 pharmacogenetics.

Authors:  Michael H Court
Journal:  Vet Clin North Am Small Anim Pract       Date:  2013-06-13       Impact factor: 2.093

8.  Biochemical characterization of variants of canine CYP1A1 using heterologous expression.

Authors:  Hee Jeong Yu; Seung Heon Lee; Seungwoo Lee; Yu Jung Choi; Dayoung Oh; Ki-Hoan Nam; YoungMin Yun; Doug-Young Ryu
Journal:  J Vet Med Sci       Date:  2017-06-24       Impact factor: 1.267

9.  Functional impact of cytochrome P450 3A (CYP3A) missense variants in cattle.

Authors:  Mery Giantin; Minna Rahnasto-Rilla; Roberta Tolosi; Lorena Lucatello; Marianna Pauletto; Giorgia Guerra; Francesca Pezzato; Rosa M Lopparelli; Roberta Merlanti; Paolo Carnier; Francesca Capolongo; Paavo Honkakoski; Mauro Dacasto
Journal:  Sci Rep       Date:  2019-12-23       Impact factor: 4.379

10.  Analysis of polymorphisms of canine Cytochrome P 450-CYP2D15.

Authors:  Marjan A E van Hagen; Louska Schipper; Marjolein A M Oosterveer-van der Doelen; Manon Vos-Loohuis; Ronette Gehring; Peter A Leegwater
Journal:  J Vet Pharmacol Ther       Date:  2020-07-12       Impact factor: 1.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.